ID: MRFR/Pharma/2452-HCR | February 2021 | Region: Global | 110 pages
Market Synopsis of Global Mitochondrial Myopathies Market:
Mitochondrial myopathy is an umbrella term for rare genetic diseases caused due to defective mitochondria in cells which results in inability of the mitochondria to consume normal levels of oxygen and produce energy. The disease manifests itself from infancy to adulthood.
The market driving factors for global mitochondrial myopathy market are the growing number of cases that are detected, rising number of screening for genetic diseases, incentives provided by governments for rare genetic diseases etc. The market restraints are the poor number of treatment options due to rare nature of the disease, absence of curative treatment etc.
Considering all these factors the market for mitochondrial myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Figure 1 Global Mitochondrial myopathies Market by Type, 2016 (% Market Share)
The global mitochondrial myopathies market is segmented on the basis of type and therapies. Based on type, the market has been segmented as Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA depletion syndrome (MDS), Mitochondrial encephalomyopathy, Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), Myoclonus epilepsy with ragged red fibers (MERRF), Neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, Progressive external ophthalmoplegia (PEO). Based on the therapies, the market has been segmented as dietary, supportive, vitamins, coenzymes and antioxidants and other.
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is the fastest region because of large unmet needs which is led by China and India. The Middle East and Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions.
Key players of Global Mitochondrial myopathies Market:
Key players profiled in the report are Reata Pharmaceuticals, Inc., Stealth BioTherapeutics, Raptor Pharmaceutical Corp., GeneDx, NeuroVive Pharmaceutical AB, and others.
The report for Global mitochondrial myopathies market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Frequently Asked Questions (FAQ) :
Mitochondrial myopathies market valuation can touch USD 600 million by 2023.
Mitochondrial myopathies market can exhibit a CAGR of 3.2% from 2017 to 2023.
Screening tests for genetic diseases, increasing prevalence of mitochondrial myopathies, and incentives by governments for finding solutions are major drivers of the global mitochondrial myopathies market.
Limited treatment options and absence of curative treatment can hamper the global mitochondrial myopathies market growth.
The Americas can dominate the global mitochondrial myopathies market owing to favorable reimbursement schemes and large healthcare expenditure.
Stealth BioTherapeutics, Raptor Pharmaceutical Corp., Reata Pharmaceuticals, Inc., GeneDx, NeuroVive Pharmaceutical AB, and others are notable players of the global mitochondrial myopathies market.
Table of Contents
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2. RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3. MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4. MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL FLEXIBLE SPINAL IMPLANTS MARKET, BY TYPE
5.2 KEARNS-SAYRE SYNDROME (KSS)
5.3 LEIGH SYNDROME
5.4 MITOCHONDRIAL DNA DEPLETION SYNDROME (MDS)
5.5 MITOCHONDRIAL ENCEPHALOMYOPATHY
5.6 MITOCHONDRIAL NEURO-GASTROINTESTINAL ENCEPHALOMYOPATHY (MNGIE)
5.7 MYOCLONUS EPILEPSY WITH RAGGED RED FIBERS (MERRF)
5.8 NEUROPATHY, ATAXIA AND RETINITIS PIGMENTOSA (NARP)
5.9 PEARSON SYNDROME, PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (PEO)
6. GLOBAL FLEXIBLE SPINAL IMPLANTS MARKET, BY THERAPIES
6.3 VITAMINS, COENZYMES AND ANTIOXIDANTS
7. GLOBAL FLEXIBLE SPINAL IMPLANTS MARKET, BY DIAGNOSTIC TESTS
7.1 MUSCLE BIOPSY
7.2 BLOOD ENZYME TEST
7.3 GENETIC TEST
8. GLOBAL FLEXIBLE SPINAL IMPLANTS MARKET, BY REGION
8.1 NORTH AMERICA
8.4 MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10. COMPANY PROFILE
10.1 REATA PHARMACEUTICALS, INC.
10.1.2 PRODUCT OVERVIEW
10.1.4 KEY DEVELOPMENTS
10.2 STEALTH BIOTHERAPEUTICS
10.2.2 PRODUCT OVERVIEW
10.2.4 KEY DEVELOPMENTS
10.3 RAPTOR PHARMACEUTICAL CORP.
10.3.2 PRODUCT OVERVIEW
10.3.4 KEY DEVELOPMENT
10.4 RAYM GENEDX
10.4.2 PRODUCT OVERVIEW
10.4.4 KEY DEVELOPMENTS
10.5 NEUROVIVE PHARMACEUTICAL AB
10.5.2 PRODUCT OVERVIEW
10.5.4 KEY DEVELOPMENTS
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF FLEXIBLE SPINAL IMPLANTS INDUSTRY